Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in EPO-Refractory Lower-Risk MDS
NCT02431351Phase 2Withdrawn
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selinexor in myelodysplastic syndrome (MDS), sponsored by Karyopharm Therapeutics Inc.. Planned start Nov 2015; status: withdrawn.
02
Drugs
selinexor
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02431351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431351.